Compare RTX & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RTX | MRK |
|---|---|---|
| Founded | 1934 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.1B | 268.7B |
| IPO Year | 1994 | 1994 |
| Metric | RTX | MRK |
|---|---|---|
| Price | $207.07 | $117.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 14 |
| Target Price | ★ $190.69 | $123.21 |
| AVG Volume (30 Days) | 6.2M | ★ 9.1M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | 1.30% | ★ 2.94% |
| EPS Growth | ★ 39.72 | 8.01 |
| EPS | 4.96 | ★ 7.28 |
| Revenue | ★ $80,738,000,000.00 | $65,011,000,000.00 |
| Revenue This Year | $6.42 | $3.74 |
| Revenue Next Year | $6.66 | $5.47 |
| P/E Ratio | $42.18 | ★ $15.92 |
| Revenue Growth | ★ 17.15 | 1.31 |
| 52 Week Low | $112.27 | $75.40 |
| 52 Week High | $214.50 | $125.14 |
| Indicator | RTX | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 56.68 | 49.78 |
| Support Level | $193.07 | $105.23 |
| Resistance Level | $214.50 | $125.14 |
| Average True Range (ATR) | 5.08 | 2.81 |
| MACD | 0.21 | -1.10 |
| Stochastic Oscillator | 67.80 | 34.85 |
RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure across three segments, mostly as a supplier to commercial aerospace and to the defense market: Collins Aerospace, a diversified aerospace supplier; Pratt & Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).